Patent · US Active

Piperidin-4-yl azetidine derivatives as JAK1 inhibitors

US8765734B2 · kind B2 · utility

104Cited by

44References

12Claims

0Family size

Assignee

Incyte Corporation · US

Inventors

Taisheng Huang · Wilmington, US
Chu-Biao Xue · Hockessin, US
Hui Li · Santa Clara, US
Qun Li · Beijing, CN

Key dates

Filing date	Mar 9, 2011
Grant date	Jul 1, 2014
Priority date	—
Expiry date	Mar 25, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.